Tilray | TRLY - 销售和管理费用

股票价格

9.23

每天变化

-0.23 -2.43%

每月一次

-3.75%

每年

1,237.68%

Q2 预测

9.04

金融业

USD

USD 2.1B

现金及等价物

USD 264.83M

USD 164.37M

USD 729.32M

USD 259.32M

USD 640.95M

USD -20.01M

USD 8.37M

USD 2.84K

EPS每股收益

USD -0.41

股本和储备

USD 1.58B

USD 57.47M

债务利息支出

USD 6.7M

USD 12.83M

USD 268.59M

USD 7.16B

USD -44.93M

USD 237.52M

USD -20.01M

普通股股本

USD 116.52M

11.57

USD -39.96M

USD 217.51M

销售和管理费用

USD 24.85M

USD 282.79M

贸易债权人

USD 114.5M

应收帐款人

USD 109.07M

	销售和管理费用	更改		日
Acasti Pharma	USD 1.96M		180K	2025-09
Akebia Therapeutics	USD 23.53M		3.19M	2025-12
Alaunos Therapeutics	USD 585K		84K	2025-09
Aurora Cannabis	CAD 40.62M		1.17M	2025-12
Avita Medical	AUD 19.03M		1.95M	2025-12
Canopy Growth	CAD 28.9M		636K	2025-12
Cronos Group	USD 19.45M		4.9M	2025-12
Dianthus Therapeutics	USD 6.57M		1.62M	2025-12
Divis Laboratories Ltd	INR 3.4B		10M	2025-06
Ionis Pharmaceuticals	USD 130M		43.43M	2025-12
IQVIA Holdings	USD 468M		46M	2025-12
Knight Therapeutics	CAD 35.45M		4.43M	2025-12
Moderna	USD 308M		40M	2025-12
Organigram Holdings	CAD 7.73M		1.13M	2025-12
Organon & Co	USD 399M		54M	2025-09
Revvity	USD 251.73M		9.82M	2025-12
Tectonic Therapeutic	USD 3.44M		1.52M	2025-12
Tilray	USD 24.85M		1.7M	2025-09
Viatris	USD 1.03B		144.1M	2025-12
Xeris Pharmaceuticals	USD 42.64M		3.82M	2025-12
Zealand Pharma A/S	91.81M		99.04M	2025-12